Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study

Abstract

BackgroundAtherosclerotic cardiovascular diseases (ASCVD) and dyslipidemia are associated to a higher risk of cardiovascular events, mortality, use of healthcare resources and costs. In Spain, the evidence about the administration of lipid-lowering treatments in clinical practice, and their clinical effectiveness in patients with ASCVD and hypercholesterolemia and patients with FH is scarce. Therefore, a multidisciplinary working group of cardiologists, family physicians, internal medicine specialists and neurologists was gathered for the Reality study. The aim of this study is to describe the demographic and clinical characteristics, comorbidities, and concomitant medication of patients with ASCVD and hypercholesterolemia and of patients with familial hypercholesterolemia (FH). The use of healthcare resources and costs associated to the management of these diseases after their diagnosis were also considered.MethodsThis is an observational and retrospective study, based on the BIG-PAC® database, which includes the electronic medical registries (EMRs) of 1.8 million people from 7 Autonomous Communities in Spain (including public primary care centers and hospitals). The study includes patients who had a new or recurrent episode of ASCVD during the recruitment period (from 01/01/2017 to 31/12/2018). The index date will be defined as the date of the ASCVD event, and the follow-up period will be 24 months. According to their first diagnosis in the database, patients will be classified as ASCVD (5 groups: stable/unstable angina, acute myocardial infarction, ischemic stroke, transient ischemic attack, and peripheral arterial disease) or FH.DiscussionThis study aims to analyze the treatment patterns and use of healthcare resources of ASCVD and FH in Spain. The prevalence of these disorders will also be estimated. Due to the high morbidity and mortality associated with these diseases, it is expected that our study will provide useful information for healthcare systems and decision makers to improve the management of these disabling diseases.

The effects of saffron supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis

“…Cardiovascular disease (CVD) is known as one of the main causes of morbidity and mortality in societies ( 1 ). This complication which includes ischemic heart disease, stroke, heart failure, peripheral arterial disease, and other conditions ( 2 ), reduces the quality of life and life expectancy among patients and also leads to high medical care expenses on health systems and governments in different countries around the world ( 3 , 4 ). Numbers show that the global prevalence of CVD almost doubled from 271 million in 1990 to 523 million in 2019 besides reaching a mortality rate from 12.1 to 18.6 million which was a third of all death globally ( 5 ).…”

Cardiovascular Risk in Patients with Dyslipidemia and Their Degree of Control as Perceived by Primary Care Physicians in a Survey—TERESA-Opinion Study

“…The responses provided seem not only to be in line with reality and with published data, but also to be sincere, since they acknowledge that the most widely used strategy is moderate-intensity statins, as in other developed countries [28]; this could justify the low degree of control of patients with dyslipidemia in our country [29]. We consider that, with the availability of new therapies, it is very important to know the degree of control of dyslipidemia bearing in mind the new targets, to reveal the actual situation and to take measures to improve the cardiovascular prognosis in our population [30].…”

Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain

“…The study protocol, including the inclusion and exclusion criteria, was the subject of a previous publication ( 16 ). Patients who during the identification period (between 1-Jan-2017 and 31-Dec-2018) had a new or recurrent ASCVD episode were enrolled in the study, considering the date of that episode as the index date from which a follow-up period of 24 months started (until 31-Dec-2020 at the latest).…”